Answers are grounded in this paper and cite their sources.
Until recently, chronic daily intravenous infusions of ganciclovir or foscarnet were the only available treatment regimens for cytomegalovirus (CMV) retinitis, a sight-threatening complication that has historically affected approximately one-third of all AIDS patients in industrialized countries. In recent years, results of many randomized clinical trials of new treatments for AIDS-related CMV retinitis have been disseminated. These trials have involved four novel treatment modalities (i.e., an oral formulation of ganciclovir, a ganciclovir intraocular device, a combined intravenous ganciclovir/foscarnet regimen and a new agent, cidofovir) that offer better efficacy and/or less inconvenience than standard daily intravenous therapy with either ganciclovir or foscarnet. This review summarizes the main points clinicians should know about the available treatments for CMV disease.
No takes yet. Share an insight, caveat, or question.
Mark Z. Jacobson (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: